半定量PET参数在CAR-T治疗淋巴瘤后1个月和3个月细化预后:一项前瞻性单中心研究
该前瞻性单中心队列研究纳入61例接受阿基仑赛或替沙仑赛治疗的大B细胞淋巴瘤患者,中位随访18个月。基线和输注后1、3个月行[18F]FDG PET/CT,评估SUVmax、MTV和TLG与生存的关系。结果显示1个月和3个月时的半定量PET参数均与OS、PFS显著相关,3个月参数还与DoR相关;3个月SUVmax≥6.3和MTV≥120.1分别与死亡风险升高约8倍和近10倍相关。
要点
- CAR-T后1个月和3个月SUVmax、MTV、TLG均与OS、PFS显著相关。
- 3个月SUVmax≥6.3者死亡风险HR 8.15,MTV≥120.1者HR 9.87。
- 3个月PET参数还与DoR相关,预后区分度略优于1个月但差异无统计学意义。
核心结论
- CAR-T细胞治疗后1个月和3个月的半定量PET参数(SUVmax、MTV、TLG)与OS、PFS和DoR显著相关。
- 3个月时[18F]FDG PET/CT可能提供略强的预后区分度,但两个时间点均可用于早期风险分层。
研究设计与样本
- 前瞻性单中心队列研究,纳入61例接受阿基仑赛或替沙仑赛治疗的大B细胞淋巴瘤患者。
- 在基线和输注后1个月、3个月行[18F]FDG PET/CT,MTV和TLG以SUVmax≥4为阈值计算。
- 影像评估基于Lugano推荐,采用单因素和多因素Cox回归分析预后因素,中位随访18个月。
主要发现
- 28例(46%)患者死亡。
- Kaplan-Meier分析显示Deauville评分(DS)、SUVmax、MTV和TLG升高均与OS显著相关(均P<0.05),DS截断值固定为4。
- PET1m的SUVmax、MTV、TLG最佳截断值分别为9.1、60.8、97.0;PET3m分别为6.3、120.1、436.9。
- PET3m SUVmax≥6.3者死亡风险HR 8.15(95%CI 2.81-23.6,P<0.01),MTV≥120.1者HR 9.87(95%CI 3.65-26.7,P<0.01)。
- PET1m和PET3m的DS、SUVmax、MTV、TLG均与OS和PFS相关(均P<0.05),PET3m参数还与DoR相关(P<0.05);PET3m的Harrell C-index高于PET1m但差异无统计学意义(P>0.05)。
关键数值与推荐
- DS截断值固定为4。
- PET1m的SUVmax、MTV、TLG最佳截断值分别为9.1、60.8、97.0。
- PET3m的SUVmax、MTV、TLG最佳截断值分别为6.3、120.1、436.9。
临床怎么用
- 原文结论指出,CAR-T后1个月和3个月的半定量PET参数可用于早期风险分层。
- 原文结论指出,3个月时[18F]FDG PET/CT可能提供略强的预后区分度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR T) therapy has shown remarkable efficacy in treating relapsed or refractory large B-cell lymphoma. However, for nearly half of these patients, the therapy eventually does not achieve durable remission. We investigated whether semiquantitative PET parameters (namely, SUVmax, metabolic tumor volume [MTV], and total lesion glycolysis [TLG]) could improve risk stratification 1 mo (PET1m) and 3 mo (PET3m) after CAR T infusion. Methods: In this prospective, single-center cohort study, patients with large B-cell lymphoma received axicabtagene ciloleucel or tisagenlecleucel. [18F]FDG PET/CT scans were acquired at baseline, 1 mo, and 3 mo after infusion. MTV and TLG were calculated using a threshold SUVmax of 4 or greater. Patients were followed for overall survival (OS), progression-free survival (PFS), and duration of response (DoR). The imaging assessment was based on the Lugano recommendation for response assessment. Prognostic factors were identified using univariate and multivariate Cox regression. Results: Sixty-one patients were enrolled, with a median follow-up of 18 mo. Twenty-eight (46%) patients died. Kaplan-Meier analysis with log-rank tests indicated a significant association of elevated Deauville score (DS), SUVmax, MTV, and TLG with OS (all P < 0.05). DS cutoff was arbitrarily fixed at 4. The optimal SUVmax, MTV, and TLG cutoffs at PET1m were 9.1, 60.8, and 97.0, respectively; whereas at PET3m, they were 6.3, 120.1, and 436.9, respectively. Patients with an SUVmax of 6.3 or greater at PET3m had an 8-fold increase in risk of death (hazard ratio [HR], 8.15; 95% CI, 2.81-23.6; P < 0.01) compared with those below this cutoff. Similarly, higher MTV (≥120.1) at PET3m yielded a nearly 10-fold risk (HR, 9.87; 95% CI, 3.65-26.7; P < 0.01). DS, SUVmax, MTV, and TLG at both PET1m and PET3m were associated with OS and PFS (all P < 0.05), whereas PET3m parameters also correlated with DoR (P < 0.05). Harrell C-index values were higher for PET3m measures than for PET1m, though differences were not statistically significant (P > 0.05). On multivariable analysis, older age (HR, 1.10), bridging therapy (HR, 10.91), elevated lactate dehydrogenase (HR, 6.43), increased fibrinogen (HR, 5.27), and higher SUVmax at PET3m (HR, 11.03) independently predicted poorer OS. There were no significant associations between SUVmax, MTV, and TLG with CAR T-related toxicities. Conclusion: Semiquantitative PET parameters, such as SUVmax, MTV, and TLG, at 1 mo and 3 mo after CAR T-cell therapy correlate significantly with OS, PFS, and DoR. [18F]FDG PET/CT at 3 mo may offer slightly stronger prognostic discrimination, but both time points can be used for early risk stratification.
引用
- Farolfi A, Casadei B, Malizia C, et al. Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study. J Nucl Med. 2025. PMID: 40246539. doi:10.2967/jnumed.125.269670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。